CompletedPHASE1, PHASE2NCT03141060
Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Anthony Garcia-Prats, MD, M.DUniversity of Stellenbosch
- Intervention
- Delamanid(drug)
- Enrollment
- 37 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2025
Study locations (5)
- Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India
- Sizwe CRS, Johannesburg, Gauteng, South Africa
- PHRU Matlosana CRS, Klerksdorp, North West, South Africa
- Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape, South Africa
- Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania
Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03141060 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine